Mitsubishi Tanabe Partners with Dewpoint on $480M ALS Program for Innovative Biomolecular Research

Mitsubishi Tanabe Pharma has entered into a significant partnership with Dewpoint Therapeutics, centered on a preclinical amyotrophic lateral sclerosis (ALS) program potentially valued at up to $480 million[1][2]. This collaboration includes an undisclosed upfront payment from Mitsubishi Tanabe, which will also provide milestone and royalty payments, securing them exclusive licensing rights over the program[1]. The focus is on the development of small molecule modulators targeting TAR DNA-binding protein 43 (TDP-43), a protein implicated in ALS, with Mitsubishi Tanabe assuming responsibility for global clinical development and commercialization[1][2]. Despite previous setbacks including ending partnerships with Pfizer and Merck, Dewpoint is optimistic about the potential of this groundbreaking approach in addressing so-called "undruggable" targets, aiming to improve on current ALS biomarkers[1].